303A COLLEGE ROAD EAST, PRINCETON, NJ
Material disclosure
Janetta Trochimiuk Appointed Interim Principal Accounting Officer
PDS Biotechnology Corporation Increases Authorized Common Stock to 300M Shares
Reports Second Quarter 2026 Financial Results
Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Annual Report to Security Holders
PDS Biotechnology Enters $6M Securities Purchase Agreement with YA II PN, LTD.
Q2
Q1
Amended Annual Report
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Definitive Revised Proxy Statement